Form 4: Eli Lilly Executive Daniel Skovronsky Reports Stock Transactions

Daniel Skovronsky, an executive at Eli Lilly, reported acquiring shares and restricted stock units in the company.

Summary

• Daniel Skovronsky, an Executive Vice President at Eli Lilly, reported a transaction on February 12, 2024.
• He acquired 12,910 shares of Eli Lilly common stock at a price of $737.26 per share.
• He also acquired 8,989 restricted stock units, each representing a contingent right to receive one share of Eli Lilly common stock.
• Following these transactions, Mr. Skovronsky directly owns 123,738 shares of common stock and 8,989 restricted stock units.
• He also indirectly owns 70,000 shares of common stock through a trust.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing of stock transactions, which is neither positive nor negative in itself. It reflects standard executive compensation practices.

Positives

• The acquisition of shares by an executive could be seen as a positive sign of confidence in the company's future.

Industry Context

This is a routine filing related to executive stock transactions, which is common in publicly traded companies. It provides transparency into the holdings of key personnel.

Comparison to Industry Standards

• Executive stock transactions are a standard practice in publicly traded companies, and the reporting of these transactions is mandated by the SEC.
• The size of the transaction is not unusual for an executive of a large pharmaceutical company like Eli Lilly.
• Other pharmaceutical companies such as Pfizer (PFE) and Johnson & Johnson (JNJ) also have similar reporting requirements for their executives.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment, as it indicates executive confidence in the company.

Key Dates

Keywords

Eli Lilly, LLY, Daniel Skovronsky, stock acquisition, restricted stock units, insider trading, executive compensation